Navigation Links
CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
Date:10/18/2007

ATLANTA, Oct. 18 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it will conduct its annual Cardiac Surgery Fellows Allograft Symposium on October 19, 2007, at the Company's corporate headquarters training facility in Kennesaw, Ga. The program will include discussions and demonstrations of surgical techniques of aortic valve replacement and thoracoabdominal aortic aneurysm repair, as well as provide a practical laboratory in which to demonstrate and practice the techniques for proper implant site preparation and allograft implantation.

The keynote speaker will be David C. McGiffin, M.D., Associate Director, Division of Cardiothoracic Surgery and Chief, Section of Cardiopulmonary Transplantation at the University of Alabama, Birmingham, Ala. The program will be attended by 27 surgery fellows from major U.S. surgical training institutions, and will be directed by Paul E. Stelzer, M.D., Senior Faculty, Cardiothoracic Surgery, Mount Sinai School of Medicine, New York, N.Y.

Three additional distinguished cardiovascular surgeons complete the faculty of this program: John W. Fehrenbacher, M.D., Department of Cardiothoracic Surgery, CORVASC, Indianapolis, Ind; Francis Robicsek, M.D., Ph.D., Chairman, Department of Thoracic and Cardiovascular Surgery, Carolinas Medical Center, Charlotte, N.C.; and Craig R. Saunders, M.D., Chairman, Cardiothoracic Surgery, Saint Barnabas Health Care System, Newark, N.J.

"The Cardiac Surgery Fellows Allograft Symposium creates a unique atmosphere in which to engage in thought provoking discussions about complex surgical procedures with leading cardiovascular surgeons in the field," said Dr. Stelzer. "The additional opportunity to practice allograft implantation techniques in a wet lab environment offers an invaluable educational opportunity for these cardiac fellows."

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve and the SG Model 100 vascular graft, which are CE marked for distribution within the European Community.

For additional information about the company, visit CryoLife's Web site: http://www.cryolife.com

Media Contacts:

D. Ashley Lee

Executive Vice President, Chief Operating Officer and

Chief Financial Officer

CryoLife, Inc.

Phone: 770-419-3355

Katie Brazel

Fleishman-Hillard

Phone: 404-739-0150


'/>"/>
SOURCE CryoLife, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Study explains unexpected conductivity of nanoscale silicon
2. Engineers chart semiconductors on the scale of atoms
3. NameProtect releases annual list of top trademarkers
4. Doyle says new contracts saving state more than $16 million annually
5. Department of Commerce offers up to $1 million annually to aid tech entrepreneurs
6. Annual Bioethics Forum to explore genetic testing
7. Annual Conference Honors Tech Grant Winners
8. Criticare gets OK to market portable cardiac monitor
9. Software to aid brain surgery is goal of Milwaukee startup
10. UW-Madison has 7 Sloan research fellows, top in nation
11. Symposium will include venture capital "coaching"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... 9, 2016 This market research report on ... future prospects of the market in terms of revenue ... engaged in the manufacture of microbiology culture media and ... a market snapshot providing the overall information of various ... This section also provides the overall information and data ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists and  ... Experiences SHPG ) ... of children born with rare diseases, as well as the future ... a new initiative designed to positively affect the lives of children ... disease care. --> To mark the company,s founding 30 ...
(Date:2/9/2016)... , Feb. 9, 2016 ... Inhibitors-Pipeline Insights, 2016", report provides in depth ... development activities around the Protein-Tyrosine Phosphatase 1B ... product profiles in various stages of development ... II, Phase III and Preregistration. Report covers ...
(Date:2/8/2016)... PLYMOUTH MEETING, Pa. , Feb. 8, 2016 /PRNewswire-USNewswire/ ... place of standard bone cement products to prevent infection ... a question that the experts at ECRI Institute have ... Cement: Fighting Infection or Fighting Your Bottom Line?" ... or Fighting Your Bottom Line?" --> ...
Breaking Biology Technology:
(Date:2/9/2016)... Feb. 9, 2016 Vigilant Solutions announces today that ... (LPR) to develop a lead in a difficult homicide case. ... data to locate the suspect vehicle. Due to the ongoing ... have been omitted at the agency,s request. ... explains, "Our victim was found deceased at an intersection here ...
(Date:2/3/2016)... GOTHENBURG, Sweden , February 4, 2016 ... Revenues amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth ... Operating profit amounted to SEK 517.6 M (loss: 30.0). Earnings ... from operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% ...
(Date:2/2/2016)... , Feb. 2, 2016  BioMEMS ... are primarily focused on medical screening and ... point-of-care parameters. Wearable devices that facilitate and ... freedom of movement are being bolstered through ... human biomedical signal acquisition coupled with wireless ...
Breaking Biology News(10 mins):